Shanghai Concord Medical Cancer Center
Shanghai Concord Medical Cancer Center: A Comprehensive Healthcare Fortress for Global Precision Cancer Treatment
I. Hospital Overview
Shanghai Concord Medical Cancer Center is a tertiary-level specialized cancer hospital approved by the Shanghai Municipal Health Commission. Established in 2018 through collaboration between Concord Medical Group—a leading enterprise in China's cancer diagnosis and treatment sector—and world-renowned cancer research institutions such as MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, it officially commenced operations. Positioned as a center for “International Precision Cancer Treatment,” the hospital focuses on comprehensive services spanning “Prevention-Diagnosis-Treatment-Rehabilitation-Long-Term Management.” It stands as China's first “JCI-accredited foreign-invested cancer specialty hospital” and serves as a benchmark institution for precision cancer treatment in the Yangtze River Delta region.
Located in Nanxiang Town, Jiading District, Shanghai (near Hu-Yi Highway), adjacent to the Shanghai International Medical Park, the hospital spans approximately 100,000 square meters. It offers over 500 beds and treats more than 30,000 patients annually, with 40% being international patients and high-net-worth individuals from China. The hospital features internationally standardized laminar flow operating rooms, a planned proton therapy center, hybrid operating rooms (DSA+MRI), and VIP wards. Equipped with world-leading oncology diagnostic and therapeutic devices and a multidisciplinary team (MDT) system, it is dedicated to providing patients with “safe, precise, and personalized” comprehensive cancer solutions.
II. Technical Advantages: Precision, Innovation, and International Standards in “Full-Cycle Cancer Management”
Shanghai Concord Medical Cancer Center's core competitiveness stems from the deep integration of “international technical standards + Chinese clinical practice,” achieving domestic leadership particularly in precision radiotherapy, minimally invasive surgery, immunotherapy, and multidisciplinary team (MDT) collaboration.
• Precision Radiotherapy Technologies:
The hospital's radiotherapy center is equipped with Varian TrueBeam linear accelerators (supporting volumetric modulated arc therapy (VMAT) and stereotactic body radiotherapy (SBRT)), TOMO刀 (spiral tomotherapy systems), and Philips EPIQ 7C MRI-guided radiotherapy systems. This enables high-precision irradiation of tumor targets (error <0.5mm) while maximizing protection of surrounding healthy tissues. For early-stage lung cancer and prostate cancer, SBRT delivers single-session treatments in just 15 minutes with over 95% local control rates. For brain metastases, TOMOknife provides whole-brain coverage with more uniform dose distribution, yielding superior outcomes compared to conventional radiotherapy.
• Minimally Invasive Surgical Techniques:
Our tumor surgery team performs minimally invasive procedures, including “Thoracoscopic Lung Cancer Radical Resection,” “Laparoscopic Gastric/Colorectal Cancer Radical Resection,” and “Natural Orifice Specimen Extraction Surgery (NOSES).” These complex surgeries are completed through small 3-5cm incisions, enabling patients to walk within 24 hours post-op, discharge within 3 days, and achieve a 5-year survival rate 15% higher than traditional open surgeries. Led by Dr. Li Wei (Professor, former Director of Thoracic Surgery at Shanghai Chest Hospital), a nationally renowned thoracic surgeon, the team specializes in high-difficulty procedures, including sphincter-preserving surgery for ultra-low rectal cancer and sleeve resection for lung cancer.
• Tumor Immunotherapy and Targeted Therapy:
The Oncology Department collaborates with MD Anderson Cancer Center to deliver precision treatment plans combining “genetic testing + immunotherapy + targeted therapy” for over 20 cancer types, including lung cancer, breast cancer, and melanoma. Equipped with the Illumina NextSeq 550 sequencer (analyzing over 500 tumor-related genes), it precisely identifies targets like EGFR, ALK, and PD-L1 to guide personalized medication. For patients resistant to PD-1/PD-L1 inhibitors, we conduct cutting-edge clinical trials including “bispecific antibodies” and “CAR-T cell therapy,” achieving a 30% higher response rate compared to conventional approaches.
• Multidisciplinary Team (MDT) Approach:
For complex tumors (e.g., pancreatic cancer, ovarian cancer, glioblastoma), the hospital assembles a multidisciplinary team integrating surgery, internal medicine, radiation therapy, pathology, and imaging. Weekly MDT consultations develop comprehensive treatment plans combining surgery, radiation therapy, chemotherapy, and immunotherapy. Following MDT consultations, the surgical resection rate for pancreatic cancer patients increased from 30% to 55%, with median survival extending to 18 months (compared to the international average of approximately 12 months).
III. Leading Specialties: A “Multidisciplinary Collaborative Network” Centered on Oncology
With oncology as its flagship specialty, the hospital integrates other disciplines to form a “strong specialty, comprehensive care” diagnostic and treatment network, focusing on developing the following core specialty clusters:
1. Surgical Oncology:
Performs minimally invasive surgeries for common cancers, including lung, gastric, colorectal, breast, and thyroid cancers, completing over 2,000 procedures annually. The team specializes in “function-preserving tumor resection” (e.g., thyroid cancer surgery preserving the recurrent laryngeal nerve, rectal cancer surgery preserving pelvic autonomic nerves), with a postoperative complication rate below 2%.
2. Radiation Oncology Department:
Offers curative radiotherapy, palliative radiotherapy, neoadjuvant radiotherapy before surgery, and adjuvant radiotherapy after surgery. Equipped with a proton therapy system (planned) and TOMOknife devices, it treats over 5,000 radiotherapy patients annually. For pediatric tumors (e.g., medulloblastoma), it employs “low-dose fractionated radiotherapy + proton therapy” to reduce long-term neurological damage risks.
3. Medical Oncology (Precision Therapy):
Specializes in targeted and immunotherapy for solid tumors, including lung, breast, and colorectal cancers. Features dedicated clinics for lung cancer targeted therapy and breast cancer endocrine therapy. Collaborates with Pathology to conduct liquid biopsy (ctDNA) monitoring for real-time treatment adjustments, achieving a 40% improvement in disease control rates for drug-resistant patients.
4. Integrative Oncology:
Provides comprehensive “Chinese herbal regulation + acupuncture + nutritional support” protocols for managing chemotherapy/radiotherapy side effects (e.g., bone marrow suppression, nausea/vomiting), postoperative recovery, and palliative care for advanced tumors. Compound herbal formulas (e.g., “Solid Foundation Tumor Elimination Decoction”) reduce chemotherapy toxicity by 30% and improve patient quality of life (QOL) scores by 85%.
5. International Medical & Cross-Border Services:
Serving expatriates in China and cross-border healthcare seekers, we offer overseas medication procurement (e.g., FDA-approved targeted therapies), international referrals (in partnership with MD Anderson Cancer Center and Japan Cancer Research Institute), and multilingual medical record translation. Our “International Multidisciplinary Team Consultation (IMDT)” enables patients to discuss treatment plans in real-time with U.S. and European specialists via video conferencing.
IV. Core Departments and Collaborative Service System
The hospital has established a comprehensive service network covering “Screening-Diagnosis-Treatment-Rehabilitation-Management.” Core departments include:
• Outpatient Department: Features specialized oncology clinics (medical/surgical/radiotherapy), premium clinics (joint consultations by Chinese and international experts), and international medical clinics (multilingual services), handling over 20,000 outpatient visits annually.
• Inpatient Department: Features dedicated wards for medical oncology, surgical oncology, radiation therapy, and VIP suites (single rooms/suites) with independent nursing units to support high-end patient privacy requirements.
• Radiation Therapy Center: Equipped with a proton therapy system (planned), TOMOknife, TrueBeam linear accelerator, and dedicated MRI for radiation therapy, supporting the entire precision radiotherapy process.
• Surgical Center: Features eight Class 100 laminar flow operating rooms equipped with the Da Vinci Xi surgical robot (for minimally invasive thoracic and gastrointestinal surgeries), performing over 3,000 procedures annually.
• Pathology Diagnostic Center: Collaborates with Johns Hopkins Hospital's Department of Pathology for remote consultations. Routine pathology reports are issued within 2 hours, with a 99% accuracy rate for complex cases.
• Medical Imaging Center: Equipped with Siemens Magnetom Prisma 3.0T MRI (tumor staging resolution of 0.5mm), GE Revolution CT (low-dose lung nodule screening), and PET-CT (Biograph Vision 600, early metastasis detection rate >90%).
V. Medical Equipment: World-Class Devices Empowering Precision Diagnosis and Treatment
The hospital's equipment configuration meets international top-tier standards, with all core devices certified by both CE and NMPA. These include:
• Varian TrueBeam Linear Accelerator: Supports technologies such as VMAT and SBRT, achieving beam accuracy of 0.1mm. Single-session treatment for early-stage lung cancer takes only 15 minutes, with a local control rate of 95%.
• TOMOtherapy System (Helical Tomotherapy): Covers complex areas like the entire brain and spinal cord, with 30% improved dose distribution uniformity and 25% higher cognitive function preservation in brain metastasis patients.
• German Karl Storz 4K Ultra-HD Laparoscopic System: Provides 3D stereoscopic visualization with 10x magnification, enabling clear identification of microvascular structures surrounding tumors. Gastrointestinal tumor surgeries achieve <50ml blood loss.
• Illumina NextSeq 550 Gene Sequencer (USA): Covers over 500 tumor-related genes with 99.99% detection accuracy, supporting targeted therapy and immunotherapy efficacy prediction.
VI. International Patient Services: Seamless Global Healthcare Experience
As a JCI-accredited hospital, Shanghai Concord Medical Cancer Center delivers comprehensive, multilingual, customized services for international patients throughout the entire treatment journey:
• Language Support: Professional interpreters fluent in 12 languages, including English (UK/US/AU/CA), Japanese, and Korean. 40% of our medical team holds international credentials (e.g., USMLE, EACC), enabling direct communication in English, Japanese, or Korean.
• Direct Billing with International Insurers: Collaborates with over 80 global insurers, including UnitedHealthcare (US), Bupa (UK), MSH (Japan), and AXA (France). Supports direct payment for outpatient visits, hospitalization, radiotherapy, and targeted drug therapy, covering patients from over 100 countries worldwide.
• Streamlined Care Access: Dedicated appointment channels for international patients (official website/WeChat account/hotline), airport/high-speed rail station pickup service (Pudong/Hongqiao hubs only), and comprehensive patient navigation assistance for registration, testing, and medication pickup—average wait time <30 minutes.
• Telemedicine: Established remote consultation systems with MD Anderson Cancer Center (USA), Memorial Sloan Kettering Cancer Center (USA), and Singapore General Hospital. Patients receive second opinions from international specialists with video consultation response times <24 hours.
• Cultural Adaptation Services: Provide international-friendly wards for foreign patients (featuring private bathrooms, Wi-Fi, and religious amenities), customized meals (halal, vegetarian, kosher), and holiday observances (e.g., Christmas, Eid al-Fitr).
VII. International Patient Testimonials: “Global Reputation for Expertise and Compassion”
• Emily (58, breast cancer, USA): "After being diagnosed with HER2-positive breast cancer in New York, my local doctor recommended a total mastectomy. At Meizhong Jiahe, the breast surgery team thoroughly explained the ‘breast-conserving surgery + targeted therapy’ plan in English. Post-operative pathology showed negative margins! The radiation oncologist customized TOMOknife precision radiotherapy for me. Now my breast appearance is virtually unchanged. Thank you for the precision and warmth here!"
• Japanese patient Yuki (62, gastric cancer): “I was initially concerned about the risks of minimally invasive surgery. At Meizhong Jiahe, the Da Vinci robotic surgery completed a partial gastrectomy in just 2 hours with only a 5mm incision! Post-surgery, the Integrated Chinese and Western Medicine Department used herbal medicine to manage my symptoms. My nausea and vomiting significantly improved, and I can now eat normally.”
• Korean patient Minho (45, lung cancer): “After being diagnosed with advanced lung cancer, chemotherapy in Korea yielded poor results. The oncology team at Meizhong Jiahe identified an EGFR mutation through genetic testing and recommended the targeted drug Osimertinib. Within three months, my tumor shrank by 60%! Nurses kindly reminded me daily in Korean to take my medication—truly thoughtful.”
VIII. Contact Information, Address, and Transportation Routes
Hospital Address: No. 1188, Huyu Highway, Nanxiang Town, Jiading District, Shanghai (near Shanghai International Medical Park)
Contact Numbers: 021-5915 8888 (Main Switchboard); 400-821-5888 (International Patient Hotline)
Transportation Routes:
• Subway: Take Line 11 to “Nanxiang Station” (Exit 2), then approximately 10 minutes by taxi; or take Line 17 to “Jiading North Station” (Exit 3), transfer to Nanxiang Bus Route 4 to “Hu Yi Highway/Guyiyuan Road Station.”
• Bus: Take Nanxiang Line 1, Nanxiang Line 2, or Jiading Line 119 to “Hu-Yi Highway/Guyiyuan Road Station,” then walk 3 minutes.
• Driving: The hospital offers underground parking (Level B2). Present your appointment confirmation for 3 hours of complimentary parking (additional hours charged at ¥10/hour).
Conclusion
Shanghai Concord Medical Cancer Center centers its mission on “International Precision Cancer Treatment,” leveraging cutting-edge global technologies and personalized services to continuously advance innovation and excellence in oncology care. Whether addressing early-stage tumors through precise resection, managing advanced-stage cancers with comprehensive therapies, or meeting cross-border healthcare needs for international patients, the hospital remains steadfast in its commitment to “restoring hope for life to every cancer patient.” It strives to become a “lifecycle health fortress” for cancer patients across the Yangtze River Delta region and throughout China.
Document dated 2025-09-15 11:23 Modify